Lack of CB 1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release

British Journal of Pharmacology

Volumn 140, Issue 2, 2003, Pages 323-328

  Schlicker, Eberhard ^a   Redmer, Agnes ^a   Werner, André ^a   Kathmann, Markus ^b  

^a UNIVERSITY OF BONN   (Germany)

^b NONE

Author keywords

Acetylcholine release; Atrium; Cannabinoid CB 1 receptors; CB 1 receptor deficient mouse; Cerebral cortex; Noradrenaline release; Presynaptic receptors; SR 141716; Vas deferens

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ACETYLCHOLINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DESIPRAMINE; HEMICHOLINIUM 3; NORADRENALIN; PROSTAGLANDIN E2; RAUWOLSCINE; RIMONABANT; TRITIUM; UNCLASSIFIED DRUG; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ACETYLCHOLINE RELEASE; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN SLICE; CONTROLLED STUDY; DRUG EFFECT; EVOKED RESPONSE; GENE DISRUPTION; MALE; MOUSE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; VAS DEFERENS; ANIMAL; C57BL MOUSE; FEMALE; GENETICS; IN VITRO STUDY; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; RAT; SECRETION;

ACETYLCHOLINE; ANIMALS; CEREBRAL CORTEX; FEMALE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHOLINES; NAPHTHALENES; NOREPINEPHRINE; PIPERIDINES; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1; TRITIUM; VAS DEFERENS;

EID: 0141957473     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705449     Document Type: Article

References (21)

1. ATES, M., HAMZA, M., SEIDEL, K., KOTALLA, C.E., LEDENT, C. & GÜHRING, H. (2003). Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. Eur. J. Neurosci., 17, 597-604.
2. CHRISTOPOULOS, A., COLES, P., LAY, L., LEW, M.J. & ANGUS, J.A. (2001). Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. Br. J. Pharmacol., 132, 1281-1291.
3. CHULAK, C., COUTURE, R. & FOUCART, S. (1998). Modulatory effect of bradykinin on noradrenaline release in isolated atria from normal and B2 knockout transgenic mice. Eur. J. Pharmacol., 346, 167-174.
4. DEWEY, W.L. (1986). Cannabinoid pharmacology. Pharmacol. Rev., 38, 151-178.
5. FERRARI, F., OTTANI, A. & GIULIANI, D. (2000). Inhibitory effects of the cannabinoid agonist HU 210 on rat sexual behaviour. Physiol. Behav., 69, 547-554.
6. HÁJOS, N., LEDENT, C. & FREUND, T.F. (2001). Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience, 106, 1-4.
7. 1 receptor. Proc. Natl. Acad. Sci., 98, 3662-3665.
8. HOWLETT, A.C., BARTH, F., BONNER, T.I., CABRAL, G., CASELLAS, P., DEVANE, W.A., FELDER, C.C., HERKENHAM, M., MACKIE, K., MARTIN, B.R., MECHOULAM, R. & PERTWEE, R.G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161-202.
9. 1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice. Naunyn-Schmiedeberg's Arch. Pharmacol., 363, 50-56.
10. 1 receptor-deficient mice. Br. J. Pharmacol., 132, 1169-1173.
11. PERTWEE, R.G. (1999). Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem., 6, 635-664.
12. 8-tetrahydrocannabinol in two isolated tissue preparations. Eur. J. Pharmacol., 315, 195-201.
13. PORTER, A.C. & FELDER, C.C. (2001). The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol. Ther., 90, 45-60.
14. 1 receptor. J. Pharmacol. Exp. Ther., 301, 1020-1024.
15. RINALDI-CARMONA, M., BARTH, F., HÉAULME, M., SHIRE, D., CALANDRA, B., CONGY, C., MARTINEZ, S., MARUANI, J., NÉLIAT, G., CAPUT, D., FERRARA, P., SOUBRIÉ, P., BRELIÉRE, J.C. & LE FUR, G. (1994). SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 350, 240-244.
16. SCHLICKER, E. & KATHMANN, M. (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci., 22, 565-572.
17. 1 rceptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn-Schmiedeberg's Arch. Pharmacol, 356, 583-589.
18. 1 receptors - evidence of an endogenous tone in humans. Naunyn-Schmiedeberg's Arch. Pharmacol., 365 (Suppl. 1), R23.
19. STELLA, N. (2001). How might cannabinoids influence sexual behavior? Proc. Natl. Acad. Sci., 98, 793-795.
20. 3H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and β-adrenoceptors in mouse tissues. Br. J. Pharmacol., 130, 321-330.
21. 1 receptor knockout mice. Proc. Natl. Acad Sci., 96, 5780-5785.